On our latest Trade To Black Podcast, we’re going to take a look at Cybin’s psychedelic breakthroughs with CYB003 with CEO Doug Drysdale, Eaze Technologies’ cannabis expansion plans, and the latest political developments in Washington, DC which might impact the industry.
Cybin’s (NYSE:CYBN) CEO Doug Drysdale explains their latest trials, where they reported a groundbreaking 71% remission rate in patients with major depressive disorder (MDD) using their leading compound, CYB003. The patients reported these results after just two doses, with effects lasting up to 12 months. It’s a stark difference compared to traditional SSRIs which have a 33% remission rate with daily dosing and significant side effects. We’ll ask what’s next regarding their Phase III trial and the performance of the psychedelic stock as CYB003’s potential could disrupt the $4 billion antidepressant market.
Cory Azzalino, CEO of Eaze Technologies, one of the most recognized brands in cannabis delivery, has secured $10 million in Series B funding to expand operations across California, Colorado, Florida, and Michigan. Supported by billionaire Jim Clark, this funding marks the culmination of a successful restructuring process. Eaze aims to position itself as the most convenient and value-driven cannabis provider in the U.S. market. Azzalino says that their competitive edge lies in its ability to integrate delivery and retail services, driving higher volume and customer satisfaction.
Finally, Adam Goers, SVP of Corporate Affairs at The Cannabist Company Holdings (OTC: CBSTF), will join us to share the latest he’s hearing from Washington, DC. With the Trump administration set to take office, do appointments like RFK Jr. and Matt Gaetz signal potential progress for federal cannabis policy? We’ll share our thoughts and Goers addresses concerns about whether Matt Gaetz will still be appointed Attorney General, as announced last week by President-Elect Donald Trump.
As the clock ticks down to the Administrative Law Judge (ALJ) hearing in two weeks, industry leaders are taking a coordinated approach to ensure positive outcomes. The hearing marks a critical step in advancing cannabis reform, and insiders are optimistic about the Trump administration’s commitment to “promises made, promises delivered.” We’ll see how things shake out after the meeting next month.